Parathyroid Disorders. Группа авторов

28Eisner B, Ahn J, Stoller M: Differentiating primary from secondary hyperparathyroidism in stone patients: the “Thiazide challenge”. J Endourol 2009;23:191–192.

29Hagag P, Revet-Zak I, Hod N, Horne T, Rapoport MJ, Weiss M: Diagnosis of normocalcemic hyperparathyroidism by oral calcium loading test. J Endocrinol Invest 2003;26:327–332.

30Gallieni M, De Luca N, Santoro D, Meneghel G, Formica M, Grandaliano G, Pizzarelli F, Cossu M, Segoloni G, Quintaliani G, Di Giulio S, Pisani A, Malaguti M, Marseglia C, Oldrizzi L, Pacilio M, Conte G, Dal Canton A, Minutolo R: Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. J Nephrol 2016;29:71–78.

31Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ: Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007;92:3001–3005.

32Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F: Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos 2012;2012:128352.

33Charopoulos I, Tournis S, Trovas G, Raptou P, Kaldrymides P, Skarandavos G, Katsalira K, Lyritis GP: Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women. J Clin Endocrinol Metab 2006;91:1748–1753.

34Díaz-Soto G, de Luis Román D, Jauregui OI, Briongo L, Romero E, Pérez-Castrillón JL: Trabecular bone score in patients with normocalcemic hyperparathyroidism. Endocr Pract 2016;22:703–707.

35Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H, Liang J, Li L, Lin W, Lin L, Shi L, Cai L, Wen J: Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 2015;100:2420–2424.

36Corbetta S, Mantovani G, Spada A: Metabolic syndrome in parathyroid diseases. Front Horm Res 2018;49:144–159.

37Mesquita PN, Dornelas Leão Leite AP, Chagas Crisostomo SD, Veras Filho E, da Cunha Xavier L, Bandeira F: Evaluation of coronary calcium score in patients with normocalcemic primary hyperparathyroidism. Vasc Health Risk Manag 2017;13:225–229.

38Pepe J, Cipriani C, Sonato C, Raimo O, Biamonte F, Minisola S: Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol 2017;177:R297–R308.

39van Ballegooijen AJ, Reinders I, Visser M, Brouwer IA: Parathyroid hormone and cardiovascular disease events: a systematic review and meta-analysis of prospective studies. Am Heart J 2013;165:655–664.

40Billington EO, Gamble GD, Reid IR: Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men. Bonekey Rep 2016;5:852.

41Cakir I, Unluhizarci K, Tanriverdi F, Elbuken G, Karaca Z, Kelestimur F: Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine 2012;42:419–422.

42Tassone F, Maccario M, Gianotti L, Baffoni C, Pellegrino M, Cassibba S, Cesario F, Magro G, Borretta G: Insulin sensitivity in normocalcaemic primary hyperparathyroidism. Endocrine 2013;44:812–814.

43Diri H, Unluhizarci K, Kelestimur F: Investigation of glucose intolerance in patients with normocalcemic primary hyperparathyroidism: 4-year follow-up. Endocrine 2014;47:971–972.

44Hirsch D, Kopel V, Nadler V, Levy S, Toledano Y, Tsvetov G: Pregnancy outcomes in women with primary hyperparathyroidism. J Clin Endocrinol Metab 2015;100:2115–2122.

45Lim JY, Herman MC, Bubis L, Epelboym I, Allendorf JD, Chabot JA, Lee JA, Kuo JH: Differences in single gland and multigland disease are seen in low biochemical profile primary hyperparathyroidism. Surgery 2017;161:70–77.

46Campennì A, Ruggeri RM, SIndoni A, Giovinazzo S, Calbo E, Ieni A, Calbo L, Tuccari G, Baldari S, Benvenga S: Parathyroid carcinoma presenting as normocalcemic hyperparathyroidism. J Bone Miner Metab 2012;30:367–372.

47Rejnmark L, Amstrup AK, Mollerup CL, Heickendorff L, Mosekilde L: Further insights into the pathogenesis of primary hyperparathyroidism: a nested case-control study. J Clin Endocrinol Metab 2013;98:87–96.

48Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E, Borderie D, Kahan A, Cormier C: Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 2013;98:3213–3220.

49Koumakis E, Souberbielle JC, Payet J, Sarfati E, Borderie D, Kahan A, Cormier C: Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism. Osteoporos Int 2014;25:1963–1968.

50Wade TJ, Yen TW, Amin AL, Wang TS: Surgical management of normocalcemic primary hyperparathyroidism. World J Surg 2012;36:761–766.

51Marcocci C, Bollerslev J, Khan AA, Shoback DM: Medical management of primary hyperparathyroidism: proceedings of the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab 2014;99:3607–3618.

52Cesareo R, Di Stasio E, Vescini F, Campagna G, Cianni R, Pasqualini V, Romitelli F, Grimaldi F, Manfrini S, Palermo A: Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int 2015;26:1295–1302.

53Konrade I, Dambrova G, Dambrova M: Denosumab-induced hypophosphataemia in a case of normocalcaemic primary hyperparathyroidism. Intern Med J 2017;47:974–975.

      Prof. Sabrina Corbetta

      Endocrinology and Diabetology Service and Laboratory of Experimental Endocrinology

      Department of Biomedical Sciences for Health, University of Milan

      IRCCS Istituto Ortopedico Galeazzi

      Via R. Galeazzi 4 , IT–20161 Milan (Italy)

      E-Mail [email protected]